Figure 4From: Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection Mean change (±SE) from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR according to treatment duration in the PILLAR study. Back to article page